FIBROBIOLOGICS doses first patients in diabetic foot ulcer trial
Tweet Send to a Friend
FibroBiologics, Inc. (NASDAQ: FBLG) announced that the first patients have been dosed in its Phase 1/2 clinical trial evaluating CYWC628 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
